{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034110","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.063291+00:00","generated_at":"2026-05-31T13:44:50.640326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ardelyx Q2 total revenue $73.2M, driven by IBSRELA $35.4M and XPHOZAH $37.1M","bullets":["IBSRELA Q2 net sales $35.4M, up ~25% QoQ; XPHOZAH Q2 net sales $37.1M, up from $15.2M in Q1 2024.","Total revenue $73.2M vs $22.3M YoY; net loss narrowed to $16.5M ($0.07/sh) from $17.1M ($0.08/sh) YoY.","FY 2024 IBSRELA revenue guidance unchanged at $140-150M; cash and investments $186M at quarter end.","Filed lawsuit against CMS over ESRD PPS rule threatening XPHOZAH access; declined TDAPA application.","SG&A expenses doubled to $64.7M primarily due to ongoing commercialization of both products."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034110","json":"https://secwatch.observer/filing/0001628280-24-034110.json","markdown":"https://secwatch.observer/filing/0001628280-24-034110.md","text":"https://secwatch.observer/filing/0001628280-24-034110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/0001628280-24-034110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024034110/ardx-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:44:50.640326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}